New pill could boost breathing in COPD patients already on inhalers
NCT ID NCT04238221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the drug doxofylline to standard inhaler therapy can improve lung function in people with stable COPD. 78 participants will take doxofylline or a placebo for 4 weeks, then switch. The main goal is to see if doxofylline increases the amount of air they can exhale in one second (FEV1).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- doxofylline (Ansimar)
- What this could lead to
- If it works, this could offer a new add-on option to help COPD patients breathe better when inhalers alone aren't enough.
- What could go wrong
- This is a small, early-phase trial with only 78 people over 4 weeks. Results may not apply to all COPD patients, and doxofylline may cause side effects like nausea or headache.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
L. Sacco Hospital
Milan, 20157, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD